Antimicrobial treatment of non-cystic fibrosis bronchiectasis

References

• Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease. and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 2010;193:356-65
   PubMed Web of Science ®Google Scholar
• Cole PJ. Inflammation: a two-edged sword – the model of bronchiectasis. Eur J Respir Dis Suppl 1986;47:6-15
   Google Scholar
• Goyal V, Grimwood K, Marchant J, et al. Does failed chronic wet cough response to antibiotics predict bronchiectasis? Arch Dis Child 2014;99:522-5
   PubMed Web of Science ®Google Scholar
• Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand national incidence of bronchiectasis “too high” for a developed country. Arch Dis Child 2005;90:737-40
   PubMed Web of Science ®Google Scholar
• Kapur N, Karadag B. Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries. Paediatr Respir Rev 2011;12:91-6
   PubMed Web of Science ®Google Scholar
• Einsiedel L, Fernandes L, Spelman T, et al. Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population. Clin Infect Dis 2012;54:43-50
   PubMed Web of Science ®Google Scholar
• Nathan AM, Muthusamy A, Thavagnanam S, et al. Chronic suppurative lung disease in a developing country. Pediatr Pulmonol 2014;49:435-40
   PubMedGoogle Scholar
• Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest 2012;142:432-9
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. Bronchiectasis. Australian Government; Canberra, Australia: 2013. p. 1-6
   Google Scholar
• Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010;104:981-5
   PubMed Web of Science ®Google Scholar
• Australian Government. Australian Institute of Health and Welfare. Bronchiectasis. Available from: www.aihw.gov.au/bronchiectasis [Last accessed 6 April 2014]
   Google Scholar
• O’Donnell AE. Bronchiectasis in patients with COPD. A distinct COPD phenotype? Chest 2011;140:1107-8
   PubMedGoogle Scholar
• Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009;136:1521-8
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12:205-9
   Google Scholar
• Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis. Chest 2010;138:158-64
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132:1565-72
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, de la Rosa CD, Soler-Cataluna JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:823-31
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Wells AU, Hansall DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34:843-9
   PubMed Web of Science ®Google Scholar
• Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014;108:287-96
   PubMed Web of Science ®Google Scholar
• Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277-84
   PubMed Web of Science ®Google Scholar
• Li AM, Sonnappa S, Lex C, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J 2005;26:8-14
   PubMed Web of Science ®Google Scholar
• Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007;101:1163-70
   PubMed Web of Science ®Google Scholar
• McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population. Chest 2012;142:159-67
   PubMedGoogle Scholar
• Singleton RJ, Valery PC, Morris PS, et al. Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatr Pulmonol 2014;49:189-200
   PubMed Web of Science ®Google Scholar
• Kapur N, Grimwood K, Masters IB, et al. Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis. Pediatr Pulmonol 2012;47:300-7
   PubMed Web of Science ®Google Scholar
• Moulton BC, Barker AF. Pathogenesis of bronchiectasis. Clin Chest Med 2012;33:211-17
   PubMedGoogle Scholar
• Field EC. Bronchiectasis in childhood. II Aetiology and pathogenesis, including a survey of 272 cases of doubtful irreversible bronchiectasis. Pediatrics 1949;4:231-48
   PubMed Web of Science ®Google Scholar
• Gaillard EA, Carty H, Heaf D, Smyth RL. Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs. Eur J Radiol 2003;47:215-20
   PubMed Web of Science ®Google Scholar
• Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax 2012;67:1006-13
   PubMed Web of Science ®Google Scholar
• Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001;164:1628-32
   PubMed Web of Science ®Google Scholar
• Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological and risk factors. Thorax 2002;57:15-19
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186:657-65
   PubMed Web of Science ®Google Scholar
• Hare KM, Grimwood K, Leach AJ, et al. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian Indigenous children with bronchiectasis. J Pediatr 2010;157:1001-5
   PubMed Web of Science ®Google Scholar
• Hare KM, Leach AJ, Morris PS, et al. Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in Indigenous Australian children with non-cystic fibrosis bronchiectasis. Int J Antimicrob Agents 2012;40:365-9
   PubMedGoogle Scholar
• Pizzutto S, Grimwood K, Bauert P, et al. Bronchoscopy contributed to the clinical management of Indigenous children newly diagnosed with bronchiectasis. Pediatr Pulmonol 2013;48:67-73
   PubMed Web of Science ®Google Scholar
• Grimwood K. Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatr Respir Rev 2011;12:111-18
   PubMedGoogle Scholar
• Marsh RL, Thornton R, Smith-Vaughan HC, et al. Detection of biofilm in bronchoalveolar lavage from children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Wurzel DF, Mackay IM, Marchant JM, et al. Adenovirus species C is associated with chronic suppurative lung diseases in children. Clin Infect Dis 2014;59:34-40
   PubMed Web of Science ®Google Scholar
• King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007;101:1633-8
   PubMed Web of Science ®Google Scholar
• Wickremasinghe M, Ozerovitch LJ, Davies G, et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 2005;60:1045-51
   PubMed Web of Science ®Google Scholar
• Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010;182:977-82
   PubMed Web of Science ®Google Scholar
• Foweraker JE, Wat D. Microbiology of non-CF bronchiectasis. Eur Respir Mon 2011;52:68-96
   Google Scholar
• Tseng BS, Parsek MR. Factors that impact Pseudomonas aeruginosa biofilm structure and function. In: Vasil ML, Darwin AJ, editors. Regulation of bacterial virulence. ASM Press; Washington DC, USA: 2013. p. 3-20
   Google Scholar
• Van Eldere J, Slack MPE, Ladhani S, Cripps AW. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Gellatly SL, Hancock REW. Pseudomonas aeruginosa: new insights into pathogenesis and host defences. Path Dis 2013;67:159-73
   PubMed Web of Science ®Google Scholar
• Kunst H, Wickremasinghe M, Wells A, Wilson R. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur Respir J 2006;28:352-7
   PubMedGoogle Scholar
• Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis 2014;6:210-20
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial infection. Am J Respir Crit Care Med 2007;175:367-416
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Nash KA, Wallace RJ. Antimicrobial susceptibility testing, drug resistance mechanisms and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 2012;25:545-82
   PubMed Web of Science ®Google Scholar
• Nessar R, Cambau E, Reyrat JM, et al. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012;67:810-18
   PubMed Web of Science ®Google Scholar
• Bains SN, Judson MA. Allergic bronchopulmonary aspergillosis. Clin Chest Med 2012;33:265-81
   PubMed Web of Science ®Google Scholar
• Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013;43:850-73
   PubMed Web of Science ®Google Scholar
• Alharbi S, Van Caeseele P, Consunji-Araneta R, et al. Epidemiology of severe pediatric adenovirus lower respiratory tract infections in Manitoba, Canada, 1991-2005. BMC Infect Dis 2012;12:55
   PubMedGoogle Scholar
• Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev 2013;26:135-62
   PubMed Web of Science ®Google Scholar
• Flight WG, Bright-Thomas RJ, Tilston P, et al. Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax 2014;69:247-53
   PubMed Web of Science ®Google Scholar
• Kapur N, Mackay IM, Sloots TP, et al. Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children. Arch Dis Child 2014;99:749-53
   PubMed Web of Science ®Google Scholar
• Kieninger E, Singer F, Tapparel C, et al. High rhinovirus burden in lower airways of children with cystic fibrosis. Chest 2013;143:782-90
   PubMed Web of Science ®Google Scholar
• Tunney MM, Einarrson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187:1118-26
   PubMed Web of Science ®Google Scholar
• Rogers GB, van der Gast C, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013;68:731-7
   PubMed Web of Science ®Google Scholar
• Van der Gast CJ, Cuthbertson L, Rogers GB, et al. Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Harris JK, Zemanick ET. Microbes in bronchiectasis: the forest or the trees? Am J Respir Crit Care Med 2013;187:1044-5
   PubMedGoogle Scholar
• Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009;33:312-17
   PubMed Web of Science ®Google Scholar
• Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65:i1-i58
   Google Scholar
• Cohen-Cymberknoh M, Simanovsky N, Hiller N, et al. Differences in disease expression between primary ciliary dyskinesia and cystic fibrosis with and without pancreatic insufficiency. Chest 2014;145:738-44
   PubMed Web of Science ®Google Scholar
• Serisier DJ. The evidence base for non-CF bronchiectasis is evolving. Respirology 2014;19:295-7
   PubMed Web of Science ®Google Scholar
• Goyal V, Grimwood K, Chang AB. Bronchiectasis: the arrival of better evidence. Lancet Respir Med 2014;2:13-14
   Google Scholar
• Haidopoulou K, Calder A, Jones A, et al. Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function. Pediatr Pulmonol 2009;44:669-75
   PubMed Web of Science ®Google Scholar
• Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J 1997;10:2376-9
   PubMed Web of Science ®Google Scholar
• Bastardo CM, Sonnappa S, Stanojevic S, et al. Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function. Thorax 2009;64:246-51
   PubMed Web of Science ®Google Scholar
• Chang AB, Bilton D. Exacerbations in cystic fibrosis. 4. Non-cystic fibrosis bronchiectasis. Thorax 2008;63:269-76
   PubMed Web of Science ®Google Scholar
• Goeminne PC, Vandooren J, Moelants EA, et al. The sputum colour chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis. Respirology 2014;19:203-10
   PubMed Web of Science ®Google Scholar
• Kapur N, Masters IB, Morris PS, et al. Defining pulmonary exacerbations in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2012;47:68-75
   PubMed Web of Science ®Google Scholar
• Chang AB, Grimwood K, Robertson CF, et al. Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial. Trials 2012;13:156
   PubMed Web of Science ®Google Scholar
• Kapur N, Masters IB, Chang AB. Exacerbations in non-cystic fibrosis bronchiectasis: clinical features and investigations. Respir Med 2009;103:1681-7
   PubMed Web of Science ®Google Scholar
• Smith MP, Hill AT. Evaluating success of therapy for bronchiectasis. What endpoints to use? Clin Chest Med 2012;33:329-49
   PubMed Web of Science ®Google Scholar
• Hill SL, Morrison HM, Burnett D, Stockley RA. Short term response of patients with bronchiectasis to treatment with amoxicillin given in standard or high doses orally or by inhalation. Thorax 1986;41:559-65
   PubMed Web of Science ®Google Scholar
• Sidhu MK, Mandal P, Hill AT. Bronchiectasis: an update on current pharmacotherapy and future perspectives. Expert Opin Pharmacother 2014;15:505-25
   PubMed Web of Science ®Google Scholar
• Tsang KW, Chan MW, Ho PL, et al. A comparative study on the efficacy of levofloxacin and ceftazadime in acute exacerbation of bronchiectasis. Eur Respir J 1999;14:1206-9
   PubMed Web of Science ®Google Scholar
• Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluorquinolones. Expert Opin Drug Saf 2013;12:497-505
   PubMed Web of Science ®Google Scholar
• Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130:1503-10
   PubMed Web of Science ®Google Scholar
• Schelstraete P, Haerynck F, Van daele S, et al. Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa. J Cyst Fibros 2013;12:1-8
   PubMedGoogle Scholar
• White L, Mirrani G, Grover M, et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012;106:356-60
   PubMed Web of Science ®Google Scholar
• Barker AF, Couch L, Fiel S, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162:481-5
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68:812-17
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JRW, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183:491-9
   PubMed Web of Science ®Google Scholar
• Hilmarsen CW, Wilke S, Egan H, et al. Molecular epidemiological analysis suggests cross-infection with Pseudomonas aeruginosa is rare in non-cystic fibrosis bronchiectasis. Eur Respir J 2014;43:900-3
   PubMedGoogle Scholar
• Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public health threat. Lancet 2006;368:874-85
   PubMed Web of Science ®Google Scholar
• Sadsad R, Sintchenko V, McDonnell GD, Gilbert GL. Effectiveness of hospital-wide methicillin-resistant Staphylococcus aureus (MRSA) infection control policies differs by ward specialty. PLoS One 2013;8:e83099
   PubMedGoogle Scholar
• Simor AE. Staphylococcal decolonisation: an effective strategy for prevention of infection? Lancet Infect Dis 2011;11:952-62
   PubMed Web of Science ®Google Scholar
• Davis MF, Iverson SA, Baron P, et al. Household transmission of methicillin-resistant Staphylococcus aureus and other staphylococci. Lancet Infect Dis 2012;12:703-16
   PubMed Web of Science ®Google Scholar
• Uhlemann A-C, Dordel J, Knox JR, et al. Molecular tracing of the emergence, diversification, and transmission of S. aureus sequence type 8 in a New York community. PNAS 2014;111:6738-43
   PubMed Web of Science ®Google Scholar
• Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010;303:2386-92
   PubMed Web of Science ®Google Scholar
• Lo DKH, Hurley MN, Muhlebach MS, Smyth AR. Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev 2013(2):CD009650
   Google Scholar
• Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) (STAR-Too). Available from: http://clinicaltrials.gov/show/NCT01349192
   Google Scholar
• Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP). Available from: http://clinicaltrials.gov/show/NCT01594827
   Google Scholar
• Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients. Available from: http://www.clinicaltrials.gov/show/NCT01746095
   Google Scholar
• Subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis. Brit Med J 1957;2:255-9
   PubMedGoogle Scholar
• Currie DC, Garbett ND, Chan KL, et al. Double-blind randomized study of prolonged higher-dose amoxicillin in purulent bronchiectasis. Q J Med 1990;76:799-816
   PubMedGoogle Scholar
• O’Donnell AE. Antimicrobial therapy for bronchiectasis. Clin Chest Med 2012;33:381-6
   PubMedGoogle Scholar
• Zaragoulidis P, Papanas N, Kioumis I, et al. Zaragoulidis. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012;68:479-503
   PubMedGoogle Scholar
• Kanoh S, Rubin BK. Mechanisms of action and clinical applications of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615
   PubMed Web of Science ®Google Scholar
• Parnham MJ, Haber VE, Giamarellos-Bouroulis EJ, et al. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 2014;143:225-46
   PubMed Web of Science ®Google Scholar
• Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for Indigenous children with non-cystic fibrosis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2013;1:610-20
   PubMed Web of Science ®Google Scholar
• Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013;1:262-74
   PubMedGoogle Scholar
• Koh YY, Lee MH, Sun YH, et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997;10:994-9
   PubMed Web of Science ®Google Scholar
• Tsang KWT, Ho P-I. Chan K-n, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999;13:361-4
   PubMed Web of Science ®Google Scholar
• Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004;59:540-1
   PubMed Web of Science ®Google Scholar
• Cymbala AA, Edmunds LC, Bauer MA, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005;4:117-22
   PubMedGoogle Scholar
• Yalcin E, Kiper N, Ozcelik U, et al. Effects of oral clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharmacol Ther 2006;31:49-55
   PubMed Web of Science ®Google Scholar
• Anwar GA, Bourke SC, Afolabi G, et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008;102:1494-6
   PubMed Web of Science ®Google Scholar
• Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis(EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380:660-7
   PubMed Web of Science ®Google Scholar
• Altenburg J, de Graaf CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA 2013;309:1251-9
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA 2013;309:1260-7
   PubMed Web of Science ®Google Scholar
• Guang-Ying Z, Qing H, Xiang-Lian L, et al. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials. Pulm Pharmacol Ther 2014. [ Epub ahead of print]
   Google Scholar
• Li H, Liu DH, Chen LL, et al. Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother 2014;58:511-17
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90
   PubMed Web of Science ®Google Scholar
• Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013;368:1704-12
   PubMed Web of Science ®Google Scholar
• Albert RK, Schuller JL; for the COPD Clinical Research Network. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014;189:1173-80
   PubMed Web of Science ®Google Scholar
• Hare KM, Singleton RJ, Grimwood K, et al. Longitudinal nasopharyngeal carriage and antibiotic resistance of respiratory bacteria in Indigenous Australian and Alaska Native children with bronchiectasis. PLoS One 2013;8:e70478
   Google Scholar
• Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;174:928-34
   PubMed Web of Science ®Google Scholar
• Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013;188:807-12
   PubMed Web of Science ®Google Scholar
• Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 2014;11:425-34
   PubMedGoogle Scholar
• Barker AF. Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB) [abstract P4136]. Presented at the European Respiratory Society Annual Congress; Barcelona, Spain; 2013
   Google Scholar
• Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bacterial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44
   PubMed Web of Science ®Google Scholar
• Wilson R, White T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41:1107-15
   PubMed Web of Science ®Google Scholar
• Hawarth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189:975-82
   PubMedGoogle Scholar
• Nick JA, Moskowitz SM, Chmiel JF, et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 2014;11:342-50
   PubMedGoogle Scholar
• Mandal P, Sidhu MK, Donaldson LS, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. Q J Med 2013;106:27-33
   Google Scholar
• Moss RB. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. Eur Respir J 2014;43:1487-500
   PubMed Web of Science ®Google Scholar
• Aksamit TR, Philley J, Griffith DE. Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials. Respir Med 2014;108:417-25
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones M, Doshi P, et al. Oseltamavir for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014(4):CD008965
   Google Scholar
• Jagannath VA, Asokan GV, Fedorowicz Z, Lee TWR. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cochrane Database Syst Rev 2014(2):CD008139
   Google Scholar
• Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014;2:395-404
   PubMed Web of Science ®Google Scholar
• Jones M, Del Mar C, Hama R. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors upon mortality. Lancet Respir Med 2014;2:e9-10
   Google Scholar
• Field CE. Bronchiectasis. Third report on a follow-up study of medical and surgical cases from childhood. Arch Dis Child 1969;44:551-61
   PubMed Web of Science ®Google Scholar
• O’Grady KAF, Chang AB, Grimwood K. Vaccines for children and adults with chronic lung disease: efficacy against exacerbations. Expert Rev Respir Med 2014;8:43-55
   PubMed Web of Science ®Google Scholar
• O’Grady KAF, Grimwood K, Cripps A, et al. Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppuratives lung disease and bronchiectasis: protocol for a randomised controlled trial. Trials 2013;14:282
   PubMed Web of Science ®Google Scholar
• Tandon MK, Phillips M, Waterer G, et al. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest 2010;137:805-11
   PubMed Web of Science ®Google Scholar
• Priebe GP, Goldberg JB. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines 2014;13:507-19
   PubMed Web of Science ®Google Scholar
• O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolised recombinant human DNase I. Chest 1998;113:1329-34
   PubMed Web of Science ®Google Scholar
• Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009(1):CD000996
   Google Scholar
• Rogers GB, Zain NMM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014;11:496-503
   PubMedGoogle Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-85
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, de Gracia J, Relat MV, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014;43:1357-67
   PubMed Web of Science ®Google Scholar
• Kuo W, Ciet P, Tiddens HAWM, et al. Monitoring cystic fibrosis lung disease by computed tomography. Am J Respir Crit Care Med 2014;189:1328-36
   PubMed Web of Science ®Google Scholar
• Rowan SA, Bradley JM, Bradbury I, et al. Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med 2014;189:586-92
   PubMedGoogle Scholar
• Llor C, Moragas A, Hernandez S, et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:716-23
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Moragas A, Bayona C, Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest 2013;144:1571-7
   PubMed Web of Science ®Google Scholar
• Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis. Available from: http://clinicaltrials.gov/show/NCT02081963
   Google Scholar
• Lonks JR, Garau J, Xercavins M, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-64
   PubMed Web of Science ®Google Scholar
• Yanagihara K, Izumikawa K, Higa F, et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med 2009;48:527-35
   PubMed Web of Science ®Google Scholar
• Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupriocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1992;36:287-90
   PubMed Web of Science ®Google Scholar
• Tong SYC, Bishop EJ, Lilliebridge RA, et al. Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in Indigenous Northern Australia: epidemiology and outcomes. J Infect Dis 2009;199:1461-70
   PubMed Web of Science ®Google Scholar
• Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J 2014;44:382-93
   PubMed Web of Science ®Google Scholar
• A Study to Determine the Safety and Tolerability of Arikace™ Versus Placebo in Patients Who Have Bronchiectasis. Available from: http://clinicaltrials.gov/show/NCT00775138
   Google Scholar
• Mirsaeidi M, Machado RF, Garcia JGN, Schraufnagel DE. Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study. PLoS One 2014;9:e91879
   PubMed Web of Science ®Google Scholar
• Van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012;186:559-65
   PubMed Web of Science ®Google Scholar
• Arikace® for Nontuberculous Mycobacteria. Available from: http://clinicaltrials.gov/show/NCT01315236
   Google Scholar
• Olivier KN, Gupta R, Daley CL, et al. A randomized, double-blind, placebo-controlled trial of liposomal amikacin for inhalation in patients with recalcitrant pulmonary non-tuberculous mycobacterial lung disease [abstract P50985]. Presented at the American Thoracic Society Meeting; San Diego, USA; 2014
   Google Scholar
• McCullough AR, Tunney MM, Quittner AL, et al. Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulm Med 2014;14:107
   PubMed Web of Science ®Google Scholar